Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $439.8 million.

  • Allogene Therapeutics' Liabilities and Shareholders Equity fell 25.35% to $439.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 20.21%. This contributed to the annual value of $548.7 million for FY2024, which is 14.64% down from last year.
  • Per Allogene Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $439.8 million for Q3 2025, which was down 6.55% from $470.6 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q1 2021 and a low of $439.8 million during Q3 2025.
  • In the last 3 years, Allogene Therapeutics' Liabilities and Shareholders Equity had a median value of $589.1 million in 2024 and averaged $606.3 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first spiked by 71.24% in 2021, then decreased by 27.25% in 2025.
  • Over the past 5 years, Allogene Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $1.1 billion in 2021, then fell by 21.82% to $821.6 million in 2022, then fell by 21.76% to $642.8 million in 2023, then declined by 14.64% to $548.7 million in 2024, then declined by 25.35% to $439.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $439.8 million in Q3 2025, compared to $470.6 million in Q2 2025 and $508.0 million in Q1 2025.